HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Estee Lauder FY 1997 sales up 3.6% to $791.4 mil. in third quarter.

This article was originally published in The Rose Sheet

  • News
  • The Rose Sheet

Executive Summary

ESTEE LAUDER AMERICAS SALES UP 6% TO $465 MIL. IN FY 1997 THIRD QUARTER (ended March 31), paced by revenues from the fragrance duo tommy and tommy girl, Estee Lauder reported April 29. Lauder's makeup artist color cosmetics brands M.A.C. and Bobbi Brown essentials also led the sales growth for the region with double-digit gains for the three months, the company said

Table

View full table

Tags:
Latest Headlines

Need Advice About Advisory Committees, US FDA? Try Having Some

FDA Advisory Committee Reform: Does Listening Session Suggest No Major Near-Term Changes?

People On The Move: Appointments At Haleon, Bayer, Abdi Ibrahim

AI News: Lauder Expands Microsoft Partnership; Prose Beauty; Supply Chain Software; More

See All
UsernamePublicRestriction

Register

RS004107

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By